Actively Recruiting
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2024-08-27
150
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.
CONDITIONS
Official Title
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with alopecia areata between 2 to 18 years old
- Patients diagnosed with alopecia areata according to AA guideline
- AA patients treated with JAK inhibitors including tofacitinib, baricitinib, ritlecitinib, abrocitinib, upadacitinib, and ifidancitinib for more than 3 months
You will not qualify if you...
- Patients who had previously received hair implants
- Patients with other types of alopecia
- Patients with other diseases that may cause alopecia, such as psoriasis or lichen planus
- Patients unable to have their SALT score estimated at baseline or follow-up
- Patients participating in other clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Second Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
R
Ru Dai, MD
CONTACT
W
Wu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here